Trelleborg Costa Rica Site Earns ISO 13485 Certification

Why It Matters

ISO 13485 certification reduces regulatory risk and boosts customer confidence, positioning Trelleborg as a reliable nearshoring partner in the competitive medical‑device market.

Key Takeaways

• Costa Rica site gains ISO 13485, confirming medical‑device quality standards
• New 107,600 sq ft plant supports nearshoring for global customers
• Certification enhances audit readiness and reduces operational risk
• Trelleborg Group recorded 2024 sales of ~US$3.2 billion

Pulse Analysis

The ISO 13485:2016 certification is the benchmark for quality management systems in the medical‑device sector. It requires documented control of design, production, and post‑market activities, ensuring that every product meets stringent safety and regulatory criteria. By achieving this certification at its Costa Rica plant, Trelleborg Medical Solutions demonstrates that its processes are audit‑ready and that risk to patients is systematically managed. This credential not only satisfies regulators in the United States, Europe, and emerging markets but also signals to OEMs that the company can reliably deliver compliant components at scale.

Opening in December 2025, the 107,600‑square‑foot facility in the Evolution Free Zone marks Trelleborg’s first foray into Central America, a region gaining traction as a nearshoring hub for medical‑device manufacturers. Proximity to the U.S. market shortens lead times, reduces freight costs, and mitigates geopolitical disruptions that can affect Asian supply chains. The plant’s ISO‑certified status gives customers confidence that products are produced in a controlled, validated environment, accelerating program timelines and supporting faster market entry for innovative therapies.

With 2024 revenues of roughly SEK 34 billion (about US$3.2 billion) and operations in 40 countries, Trelleborg Group leverages its polymer expertise to serve a broad range of high‑value industries. The Costa Rica certification reinforces its strategy to expand a globally integrated quality system, positioning the firm as a preferred partner for leading medical‑device and biopharma firms seeking resilient, compliant manufacturing footprints. As regulatory scrutiny intensifies, companies that can demonstrate consistent ISO 13485 compliance across multiple sites will likely capture greater market share, and Trelleborg appears well‑placed to do so.